Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 647 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Torisel Clear all
Completed Not applicable Interventional Results available

SRL (Sirolimus) Withdrawal

NCT02062944
View directory record Official record
Conditions
Acute Rejection of Liver Transplant, Effects of Immunosuppressant Therapy
Interventions
Sirolimus
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 27, 2026, 4:19 AM EDT
Recruiting Phase 1 Interventional

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

NCT05661461
View directory record Official record
Conditions
Tumor, Solid, Tumor, Advanced Solid Tumor
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Antonio, Texas • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 27, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional Results available

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

NCT00808899
View directory record Official record
Conditions
Neuroblastoma
Interventions
Temsirolimus, Irinotecan, Surgical Resection of Primary Tumor, Cyclophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, PBSC, Radiation Therapy, 13-cis-retinoic acid
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Not applicable Interventional Results available

Sirolimus Conversions in African-American Renal Transplant Recipients

NCT01005706
View directory record Official record
Conditions
Absence; Kidney
Interventions
rapamune, mycophenolate mofetil and steroid, tacrolimus, sirolimus and steroid
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01902160
View directory record Official record
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Not applicable Interventional Results available

Using mTOR Inhibitors in the Prevention of BK Nephropathy

NCT01649609
View directory record Official record
Conditions
BK Viremia, BK Nephropathy
Interventions
Tacrolimus, Mycophenolate acid, Sirolimus
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

NCT00743509
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cyclophosphamide and Sirolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00450320
View directory record Official record
Conditions
Sarcoma
Interventions
sirolimus
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 27, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional Results available

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

NCT01313559
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
Interventions
Pasireotide, Everolimus, Laboratory biomarker analysis
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 27, 2026, 4:19 AM EDT
Terminated Not applicable Interventional Results available

Polycystic Liver Disease in Kidney Transplant

NCT00934791
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
Tacrolimus, Sirolimus, Mycophenolate Mofetil, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 4 Interventional Results available

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

NCT00369382
View directory record Official record
Conditions
Graft Rejection, Kidney Failure
Interventions
cyclosporine or tacrolimus, sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome

NCT03047980
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Sirolimus
Drug
Lead sponsor
Anne Comi, MD
Other
Eligibility
3 Years to 31 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 4 Interventional Results available

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

NCT00896012
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus
Procedure · Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

NCT01025453
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Temsirolimus and Sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 27, 2026, 4:19 AM EDT
Recruiting Phase 1 Interventional

Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder

NCT07844694
View directory record Official record
Conditions
Familial Platelet Disorder With Associated Myeloid Malignancy
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration, Sirolimus
Procedure · Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00935792
View directory record Official record
Conditions
Lymphocytic Leukemia
Interventions
alemtuzumab, everolimus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 27, 2026, 4:19 AM EDT
Terminated Not applicable Interventional Results available

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

NCT01369433
View directory record Official record
Conditions
Solid Tumors
Interventions
Tivozanib + paclitaxel, Tivozanib + temsirolimus, Tivozanib, Tivozanib (AV-951), Tivozanib + capecitabine, Tivo
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

NCT00033267
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma
Interventions
temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 27, 2026, 4:19 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

NCT02423954
View directory record Official record
Conditions
Advanced Cancer, Pancreatic Cancer, Renal Cell Cancer, Non Small Cell Lung Cancer, Colorectal Carcinoma, Endometrial, Uterine
Interventions
Temsirolimus, Irinotecan, Irinotecan + capecitabine, nivolumab
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 27, 2026, 4:19 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

NCT05088356
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan, CliniMACS CD34 Reagent System, Tacrolimus, Cyclophosphamide, Plerixafor, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, Thiotepa, Mycophenolate Mofetil (MMF), Ruxolitinib, Sirolimus
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 27, 2026, 4:19 AM EDT
Active, not recruiting Phase 3 Interventional

Phase III Trial of Sirolimus in IBM

NCT04789070
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Kansas City, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 27, 2026, 4:19 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT00679042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islets of Langerhans transplantation
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.

NCT00830466
View directory record Official record
Conditions
Port Wine Stain
Interventions
Laser and rapamycin versus laser alone
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
13 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 27, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Topical Rapamycin to Erase Angiofibromas in TSC

NCT01526356
View directory record Official record
Conditions
Angiofibromas, Tuberous Sclerosis
Interventions
Placebo, Rapamycin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 27, 2026, 4:19 AM EDT